A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Elritercept/ placebo
tgf-β ligand
Unknown
III
-
very low-, low-, intermediate risk MDS, Transfusion dependence assess in 16wks(1U/8weeks), EPO>200, <500.
Age: ≥18 years Phase: III
Del (5q) MDS or secondary MDS, history of malignancy>=5years, Transplantation, acute infection,
陳彩雲
李佳玲
4620